Business
Guardant Health Reports Third Quarter 2021 Financial Results
Achieved record revenue of $94.8 million Growth of 35% and 58% year over year in clinical and biopharma volumes, respectively REDWOOD CITY, Calif.--(BUSINESS
About this update from Guardant Health, Inc.
[{"type":"text","content":"\nAchieved record revenue of $94.8 million\n\nGrowth of 35% and 58% year over year in clinical and biopharma volumes, respectively\n\n REDWOOD CITY, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2021.\n\nRecent Highlights\n\n\nRevenue of $94.8 million for the third quarter of 2021, an increase of 27% over the corresponding period of 2020\n\n\nReported 22,806 tests to clinical customers and 4,839 tests to biopharmaceutical customers in the third quarter of 2021, representing an increase of 35% and 58%, respectively, over the third quarter of 2020\n\n\nInitiated ORACLE study to evaluate performance of Guardant Reveal™ to predict recurrence across eleven early-stage cancers\n\n\nPresented data at ACG showing LUNAR-2 blood test is highly sensitive in detecting early-stage colorectal cancer\n\n\nAnnounced SHIELD study to validate the performance of blood-based assay in lung cancer screening, with enrollment beginning in December of 2021\n\n\nAdded Myrtle Potter, CEO of Sumitovant Biopharma, to Board of Directors\n\n\n“We delivered solid results this quarter as we continue to build on our strong foundation as the liquid biopsy leader in oncology, despite the continued impact of COVID,” said Helmy Eltoukhy, co-founder and co-CEO. “We have continued our strong cadence of data supporting our Guardant360® products and are making solid progress towards our multi-cancer goal for MRD with the initiation of our ORACLE study. We are dedicated to offering healthcare providers a complete portfolio of oncology products that will provide clinically actionable information to guide patient care.”\n\n“At Guardant, we are focused on developing a highly accurate blood test to screen for multiple cancers where lives can be saved,” said AmirAli Talasaz, co-founder and co-CEO. “Guardant’s differentiated core technology platform has the potential to significantly improve our ability to detect many cancers at their earliest stages. Successful readouts of ECLIPSE and SHIELD, as well as future studies, will unlock the tremendous opportunity for blood-based cancer screening.”\n\nThird Quarter 2021 Financial Results\n\nRev...